Mercados españoles cerrados

Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF)

Other OTC - Other OTC Precio demorado. Divisa en USD
Añadir a la lista de favoritos
51,600,00 (0,00%)
A partir del 10:25AM EST. Mercado abierto.

Recordati Industria Chimica e Farmaceutica S.p.A.

Via Matteo Civitali,1
Milan, MI 20148
Italy
39 02 487871
https://www.recordati.com

Sector(es)Healthcare
SectorDrug Manufacturers - General
Empleados a tiempo completo

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Dr. Robert Koremans M.D.CEO & Director1,96MN/A1962
Mr. Luigi Felice La CorteGroup CFO & Executive Director1,03MN/A1969
Ms. Cathrin PettyExecutive DirectorN/AN/A1973
Mr. Giampiero MazzaExecutive DirectorN/AN/A1969
Mr. Giorgio De PalmaExecutive DirectorN/AN/A1974
Ms. Bibianne BonGroup Chief Legal OfficerN/AN/AN/A
Ms. Laura ContiGroup Communications DirectorN/AN/AN/A
Mr. Gabriele FinziExecutive VP of Corporate Development, Licensing & InnovationN/AN/AN/A
Mr. Roberto TeruzziExecutive Vice President of Group Industrial OperationsN/AN/AN/A
Mr. Raffaele SabiaChief Medical OfficerN/AN/AN/A
Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis. The company also develops CARBAGLU for hyperammonemia due to NAGS deficiency; QARZIBA, an apeiron for the treatment of high-risk neuroblastoma patients with a partial response at the chemotherapeutical through myeloablative therapy and stem cell transplantation, and relapsed or refractory neuroblastoma. In addition, it offers SYLVANT for the treatment of idiopathic multicentric Castleman diseases; REAGILA for Schizophrenia; and ELIGARD for hormone-dependent prostate cancer, as well as CAPHOSOL, a medical device for treatment of oral mucositis due to chemo and radiation therapy. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.

Gobierno corporativo

El ISS Governance QualityScore de Recordati Industria Chimica e Farmaceutica S.p.A., a día 1 de marzo de 2024, es 3. Las puntuaciones base son Auditoría: 3; Tablero: 6; Derechos de los accionistas: 3; Compensación: 2.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.